drugset / Trial / NCT03686254

The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM

NCT03686254

Phase 2/3 Unknown 160 enrolled Nanfang Hospital, Southern Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

Basing on the strong evidence from former researches, patients with CRLM can benefit from the treatment of bevacizumab combined with sencond-line chemotherapy. Recently, although with the popularization of RFA, the role that RFA plays in the long term survival of patients with metastatic colorectal cancer (CRC) is still confused. In this designed, randomized, controlled, prospective, and open clinical trial, the effectiveness of RFA combined with second-line chemotherapy + bevacizumab on unresectable CRLM is going to be evaluated compared with that of second-line chemotherapy + bevacizumab. After screened by inclusion and exclusion criteria, the eligible subjects will be randomly allocated into the experimental group-with the treatment of RFA + second-line chemotherapy + bevacizumab and control group-with the treatment of second-line chemotherapy + bevacizumab equally.

Timeline

Start
2018-07-16
Primary completion
2023-10-01
Completion
2023-10-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bevacizumab Monoclonal antibody 5 mg/kg Intravenous
Comparator Bevacizumab Monoclonal antibody 7.5 mg/kg Intravenous
Comparator Calcium folinatc Unknown 400 mg/m2
Comparator Capecitabine Small molecule 1000 mg/m2
Comparator Irinotecan Small molecule 125 mg/m2
Comparator Irinotecan Small molecule 180 mg/m2
Comparator Irinotecan Small molecule 200 mg/m2
Comparator Levoleucovorin Unknown 200 mg/m2
Comparator Oxaliplatin Small molecule 85 mg/m2
Comparator Oxaliplatin Small molecule 130 mg/m2
Comparator fluorouracil Small molecule 400 mg/m2
Comparator fluorouracil Small molecule 2400 mg/m2

Indications